VTAK

ATLANTA, June 08, 2026 (GLOBE NEWSWIRE) -- Flyte, the regional air mobility subsidiary of Catheter Precision, Inc. (NYSE:VTAK), focused on making private aviation more accessible and flexible for modern travelers, today announced that it has made a strategic investment in Volato Group, Inc. (NYSE:SOAR). As part of the transaction, VTAK acquired approximately 2.9 million shares of SOAR and will own approximately 7.5% of the company's outstanding common stock. This investment provides a basis to explore potential future collaboration to improve access, efficiency, and innovation across private aviation. "This strategic investment represents an exciting opportunity for both organizations,"

8-K - Catheter Precision, Inc. (0001716621) (Filer)

Investment strengthens balance sheet as Company evaluates non-binding AI infrastructure and technology transaction opportunities Volato Group, Inc. (NYSE:SOAR) (the "Company" or "Volato"), a technology company focused on building scalable software and data solutions that improve the reliability and intelligence of high-stakes business decisions, today announced the signing of a definitive agreement to obtain a $2.2 million strategic investment lead by Catheter Precision, Inc. (NYSE:VTAK), and other institutional investors with experience investing in artificial intelligence and emerging technology companies. The investment of restricted common stock will strengthen Volato's balance shee

8-K - Catheter Precision, Inc. (0001716621) (Filer)

10-Q - Catheter Precision, Inc. (0001716621) (Filer)

NT 10-Q - Catheter Precision, Inc. (0001716621) (Filer)

Company Deploys Scalable Short-Haul Model Following Kentucky Derby to Monetize Peak Travel Window Flagship Routes from NYC, Boston, DC, and Philadelphia Positioned to Drive Immediate Revenue, High Utilization, and Dense Flight Activity NEW YORK, May 12, 2026 (GLOBE NEWSWIRE) -- Flyte, the regional air mobility subsidiary of Catheter Precision, Inc. (NYSE:VTAK) ("VTAK" or the "Company"), today announced the positioning of aircraft across the Northeast to support increased travel demand this coming weekend in anticipation of the Preakness Stakes on Saturday, May 16th. The program centers on Baltimore/Washington International Airport (BWI), the primary access point for race attendees, wit

FORT MILL, SC, May 04, 2026 (GLOBE NEWSWIRE) -- — Flyte, the regional air mobility subsidiary of Catheter Precision, Inc. (NYSE:VTAK) ("VTAK" or the "Company"), today announced increased flight capacity and the launch of a targeted hiring initiative following the shutdown of Spirit Airlines, which ceased operations on May 2, 2026 after failing to secure funding. Spirit Airlines' abrupt exit has led to widespread flight cancellations, impacted approximately 17,000 employees of which over 2,400 were pilots, and stranded passengers nationwide, marking one of the largest U.S. airline disruptions in recent decades. The disruption has reduced available capacity across key domestic routes, cont

10-K/A - Catheter Precision, Inc. (0001716621) (Filer)

Positioned to Meet Accelerating Travel Activity across New York City, The Hamptons, Nantucket and Martha's Vineyard Scalable Short-Haul Luxury Aviation Platform Targeting Key Regional Travel Markets FORT MILL, S.C., April 28, 2026 (GLOBE NEWSWIRE) -- Flyte, the regional air mobility subsidiary of Catheter Precision, Inc. (NYSE:VTAK) ("VTAK" or the "Company"), today announced the expansion of its Cirrus Vision Jet fleet ahead of peak summer demand, scaling short-haul service from New York City to East Hampton, Nantucket, Martha's Vineyard, Newport, and Cape Cod. The expansion targets one of the most concentrated luxury travel corridors in the United States, a set of routes where trips th

8-K - Catheter Precision, Inc. (0001716621) (Filer)

FORT MILL, S.C., April 21, 2026 (GLOBE NEWSWIRE) -- Catheter Precision, Inc. (NYSE:VTAK) today announced that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for key claims covering its proprietary surgical vessel closing pressure device, marking a significant milestone in the Company's intellectual property strategy. Following a rigorous examination process, the USPTO confirmed the novelty and patentability of VTAK's technology over existing prior art. The allowed claims provide protection across both the core device architecture and its method of use, creating a comprehensive and defensible intellectual property position around a foundational compo

Major Carriers Accelerate Route Cuts as Economics Break Down, Creating Multi-Billion-Dollar Opportunity in Regional Air Mobility Flyte Expands Focus on High-Frequency Short-Haul Routes to Capture Surging Demand as Industry Economics Continue to Shift FORT MILL, S.C., April 20, 2026 (GLOBE NEWSWIRE) -- Flyte, the regional air mobility subsidiary of Catheter Precision, Inc. (NYSE:VTAK), today announced it is accelerating expansion in short-haul markets as major global airlines rapidly retreat from regional routes amid rising fuel costs, operational constraints, and shifting route economics. This pullback reflects a structural shift, creating a sustained opportunity for high-frequency regio

Transaction Delivers Fully Consolidated, Revenue-Generating, Aviation Business with Accelerating Growth Positions VTAK for Scalable Expansion in Regional Air Mobility Ahead of eVTOL Commercialization FORT MILL, S.C., April 16, 2026 (GLOBE NEWSWIRE) -- Catheter Precision, Inc. (NYSE:VTAK) today announced it received shareholder approval on April 15th of the definitive agreement to acquire Fly Flyte, Inc. ("Flyte") executed on March 9. The March 9th transaction establishes Flyte as a wholly owned operating subsidiary, delivering immediate consolidation of revenue, assets, and operating performance into VTAK. Full Ownership, Consolidated Revenue and Immediate Operating Exposure Flyte ope

8-K - Catheter Precision, Inc. (0001716621) (Filer)

FORT MILL, S.C., April 13, 2026 (GLOBE NEWSWIRE) -- Catheter Precision, Inc. (NYSE:VTAK) ("VTAK" or the "Company") today announced that the results of a recently concluded VIVO study have been accepted in EP Europace, the leading European electrophysiology journal. The EP Europace journal provides an avenue of communication for top-quality European and international original, scientific work and reviews in the fields of arrhythmias, pacing and cellular electrophysiology. The journal offers readers a collection of contemporary, original, peer-reviewed papers, invited papers and editorial comments, together with book reviews and correspondence. The accepted manuscript titled "Accuracy of a

FORT MILL, S.C., April 08, 2026 (GLOBE NEWSWIRE) -- Catheter Precision, Inc. (NYSE:VTAK) ("VTAK" or the "Company") today announced that it will be attending the annual European Heart Rhythm Association (EHRA) conference in Paris, France from April 12-14, 2026. EHRA is one of several conferences supported by the European Society of Cardiology whose mission is to reduce the number of people with cardiovascular diseases by connecting cardiovascular health professionals around the world to disseminate the latest knowledge, innovations and guidelines. As a community, they work together to empower healthcare providers to transform cardiovascular care from a privilege to a universal right. Davi

FORT MILL, S.C., April 06, 2026 (GLOBE NEWSWIRE) --  Catheter Precision, Inc. (NYSE:VTAK) ("VTAK" or the "Company") today announced that the manuscript titled "Safety and Efficacy of LockeT Suture Retention Device for Large-Bore Venous Access Closure" has been accepted by the Journal of Interventional Cardiac Electrophysiology (JICE), a leading medical journal in the field of electrophysiology. This publication confirmed the safety and efficacy of LockeT for large-bore venous closure in 139 patients and concluded that LockeT demonstrated high procedural success, rapid hemostasis, early ambulation, and low complication rates for venous closure following EP procedures requiring LBVA. These

8-K - Catheter Precision, Inc. (0001716621) (Filer)

10-K - Catheter Precision, Inc. (0001716621) (Filer)

Clinical, Commercial and Regulatory Milestones Achieved in 2025 Establish a Strong Foundation in Life Sciences as Revenue Increases 95% Year Over Year Acquisition of Flyte and Strengthened Capital Position Unlock Multi-Segment Growth Strategy with Multiple Near-Term Catalysts FORT MILL, S.C., March 31, 2026 (GLOBE NEWSWIRE) -- Catheter Precision, Inc. (NYSE:VTAK) ("VTAK" or the "Company"), a U.S.-based innovative medical device company focused on electrophysiology products, today announced its financial results and operational update for the fourth quarter and full year ended December 31, 2025 as well as certain other business updates. 2025: Execution Across Clin

4 - Catheter Precision, Inc. (0001716621) (Issuer)

4 - Catheter Precision, Inc. (0001716621) (Issuer)

4 - Catheter Precision, Inc. (0001716621) (Issuer)

4 - Catheter Precision, Inc. (0001716621) (Issuer)